SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of ...

Vernalis plc today announces it has achieved a third milestone in its drug discovery collaboration with H.Lundbeck A/S (Lundbeck). Vernalis will receive a payment of £0.75m from Lundbeck in ...

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that a New Drug Application ("NDA") has been submitted to the U.S. Food and Drug Administration ("FDA") for Tuzistra™ XR ("CCP-01"), ...

* VERNALIS PLC - BOARD ALSO ANNOUNCES THAT AS PART OF STRATEGIC REVIEW IT HAS DECIDED TO SEEK OFFERS FOR COMPANY * VERNALIS PLC - HAS APPOINTED EVERCORE AS ITS FINANCIAL ADVISER FOR STRATEGIC REVIEW ...

Vernalis plc ("Vernalis" or the "Company") today announces successful completion of the CCP-07 Pivotal Single-Dose comparative bioavailability study. CCP-07 is the second product being developed for ...

MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this ...

Winnersh, UK, 14 November 2008, Vernalis plc (LSE: VER) today announces two key appointments. Firstly, Ian Garland (43) is named as Chief Executive Officer. It is expected that he will take up his ...

Vernalis plc (LSE: VER) (OTC PINK: VNLPY) announces its unaudited interim results for the six months ended 31 December 2015 will be released on Thursday, 17 March 2016. The results announcement will ...

Tuzistra XR offers extended relief of cough in adults with dosing every 12 hours and marks Vernalis' entrance into the U.S. Prescription Cough Cold Market Vernalis plc and Tris Pharma Inc. today ...

WINNERSH, UNITED KINGDOM--(Marketwired - Oct 10, 2014) - Vernalis plc (LSE: VER) today announces it has opened its US office in Berwyn, Pennsylvania and has strengthened its US Executive team with the ...

Vernalis plc and Servier are pleased to announce that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target. This agreement ...